TARGETING CNS DISORDERS

Ceremedy’s expert team strives to develop new treatments for CNS disorders, backed with the right medicinal chemistry and neuropharmacology experience to facilitate the full process from idea to drug candidate.

About

Ceremedy is a Copenhagen-based biotech company focused on drug discovery for
the treatment of CNS disorders. The company was founded in 2018 as a spin-off
from the University of Copenhagen.

Science

We perform intelligent medicinal chemistry and structure-based drug design. With it, we target an important brain
protein with a broad range of implications for treating CNS disorders.

News

  • In August 2018, the Novo Nordisk Foundation awarded a pre-seed grant of 3.5 mio DKK to support the research behind Ceremedy ApS. The grant is awarded to the University of Copenhagen and shared between Birgitte Kornum, Petrine Wellendorph and Bente Frølund.

Team

Bente Frølund

VP Medicinal Chemistry
Professor at the University of Copenhagen, with more than20 years of expertise in small-molecule medicinal chemistry.

Casper Tind Hansen

CEO
Entrepeneur-in-Residence BiOrigin, with 15 years of expertise from pharma, venture investments, and management of biotech companies. Previously CEO of Pcovery ApS and part of the Novo Ventures investment.

Petrine Wellendorph

CSO
Associate Professor at the University of Copenhagen, with more than 15 years of expertise in molecular pharmacology.

Birgitte Rahbek Kornum

VP Translational Pharmacology
Associate Professor at the University of Copenhagen, with 15 years of expertise in human biology and in vivo neuroscience.

Contact

Ceremedy ApS